[Anti-arrhythmic and hemodynamic effects of visken and glucagon in rhythm disorders in the acute phase of myocardial infarct].
Combination of the beta-adrenergic blocking agent visken with glucagon in the acute period of myocardial infarction possesses higher antiarrhythmic activity with a negligible cardiodepressive effect as compared to that of isolated administration of visken and leads to a decrease in the excessive production of catecholamines and glucocorticoids in the blood.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D002395:Catecholamines / Q000097:blood; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005934:Glucagon / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications*; D010869:Pindolol / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D002395:Catecholamines; D005938:Glucocorticoids; D005934:Glucagon; D010869:Pindolol
Antiaritmicheskie i gemodinamicheskie éffekty viskena i gliukagona pri narusheniiakh ritma v ostroĭ faze infarkta miokarda.